Gabriella Mariani, MD
AstraZeneca UK, MSD
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gabriella Mariani, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:41 UTC. Open this list on ClinicalTrials.gov
- N/ANCT02300831 · LUMINIST: LUng Cancer Molecular Insights Non Interventional StudyAstraZeneca · completed · NSCLC · study chair
- Ph3NCT01933932 · Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLCAstraZeneca · active not recruiting · Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV · study chair
- Ph1NCT01809210 · Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung CancerAstraZeneca · completed · Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV · study director
- Ph2NCT01750281 · Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.AstraZeneca · completed · Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.